MiNK Achieves Complete Remission With Allogeneic Off-The-Shelf AgenT-797 In Testicular Cancer Patient

Today MiNK Therapeutics announced that a patient from its phase 1 trial with testicular cancer, who had received its off-the-shelf

Mereo and Partner Ultragenyx Hit A Stump But Setrusumab For OI Treatment Presses On

To Expand Cardiopulmonary Pipeline Merck Acquires Verona Pharma For $10 Billion

ProKidney Scores Win With Cell Therapy Rilparencel For CKD Patients

Apogee’s IL-13 APG777 Could Challenge Top Contenders In Autoimmune Disorder Targeting Space

Latest news

MiNK Achieves Complete Remission With Allogeneic Off-The-Shelf AgenT-797 In Testicular Cancer Patient

Mereo and Partner Ultragenyx Hit A Stump But Setrusumab For OI Treatment Presses On

To Expand Cardiopulmonary Pipeline Merck Acquires Verona Pharma For $10 Billion

ProKidney Scores Win With Cell Therapy Rilparencel For CKD Patients

Top editors picks!

  • Featured, Top 1
  • Latest news, Other articles, Top editors picks!

MiNK Achieves Complete Remission With Allogeneic Off-The-Shelf AgenT-797 In Testicular Cancer Patient

1

  • Featured, Top 2
  • Latest news, Other articles, Top editors picks!

To Expand Cardiopulmonary Pipeline Merck Acquires Verona Pharma For $10 Billion

2

  • Featured, Top 2
  • Latest news, Other articles, Top editors picks!

ProKidney Scores Win With Cell Therapy Rilparencel For CKD Patients

3

  • Featured, Top 4
  • Latest news, Other articles, Top editors picks!

Apogee’s IL-13 APG777 Could Challenge Top Contenders In Autoimmune Disorder Targeting Space

4

Other articles

MiNK Achieves Complete Remission With Allogeneic Off-The-Shelf AgenT-797 In Testicular Cancer Patient

Mereo and Partner Ultragenyx Hit A Stump But Setrusumab For OI Treatment Presses On

To Expand Cardiopulmonary Pipeline Merck Acquires Verona Pharma For $10 Billion

ProKidney Scores Win With Cell Therapy Rilparencel For CKD Patients

Apogee’s IL-13 APG777 Could Challenge Top Contenders In Autoimmune Disorder Targeting Space

To Get Wet-AMD Gene Therapy To Finish Line 4DMT Reduces Workforce By 25%

Biogen To Move Salanersen Forward As Alternative SMA Therapy To ZOLGENSMA Non Responders

Nektar’s Rezpeg Hopes Revived After Latest Atopic Dermatitis Treatment Data

Merck Gets RSV Vaccine Approval From FDA Pitting It Against Beyfortus

Join Newsletter Today!

Enter your email and get information about the newest posts.
Scroll to Top